Individual difference in drug metabolism and disposition:: Toxicological significance of genotypes and phenotypes of S-mephenytoin 4′-hydroxylase (CYP2C19)

被引：1

作者：

Ikebuchi, J ^{[1
]}

Yamada, M ^{[1
]}

Ogura, Y ^{[1
]}

Yamamoto, Y ^{[1
]}

Nishimura, A ^{[1
]}

Nishi, K ^{[1
]}

Yamada, K ^{[1
]}

Irizawa, Y ^{[1
]}

机构：

[1] Tottori Univ, Fac Med, Dept Legal Med, Yonago, Tottori 6830826, Japan

来源：

PROGRESS IN FORENSIC GENETICS 9 | 2003年 / 1239卷

关键词：

CYP2C19; genotyping; phenotyping; polymorphism; toxicogenetics;

D O I：

10.1016/S0531-5131(02)00389-8

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

We examined the relationship between the genetic polymorphism of CYP2C19 and metabolism of omeprazole in order to assess the severity and to predict the outcome of poisoning for forensic and clinical toxicology. The genotypes observed were CYP2C19*1A (wild type), CYP2C19*2 (ml), and CYP2C19*3 (m2). The omeprazole hydroxylation index of the wild-type was -1.15, whereas for the hetero-type it was -0.78, and homo-mutated type 1.22. The genotype of CYP2C19 correlated with the phenotype. The present results proved that genotyping assays of drug metabolizing enzymes are of great value in toxicological significance. (C) 2003 Elsevier Science B.V. All rights reserved.

引用

页码：589 / 592

页数：4

共 50 条

[41] The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose
Feng, HJ
Huang, SL
Wang, W
Zhou, HH
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (01) : 27 - 29
[42] PHENOTYPING OF CYP2C19 WITH ENANTIOSPECIFIC HPLC-QUANTIFICATION OF R-MEPHENYTOIN AND S-MEPHENYTOIN AND COMPARISON WITH THE INTRON4/EXON5 G-]A-SPLICE SITE MUTATION
BROCKMOLLER, J
ROST, KL
GROSS, D
SCHENKEL, A
ROOTS, I
PHARMACOGENETICS, 1995, 5 (02): : 80 - 88
[43] Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism
Goldstein, JA
Blaisdell, J
CYTOCHROME P450, PT B, 1996, 272 : 210 - 218
[44] CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques
Uno, Yasuhiro
Matsushita, Akinori
Shukuya, Mitsunori
Matsumoto, Yasuka
Murayama, None
Yamazaki, Hiroshi
BIOCHEMICAL PHARMACOLOGY, 2014, 91 (02) : 242 - 248
[45] A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine
Kanacher, Tobias
Lindauer, Andreas
Mezzalana, Enrica
Michon, Ingrid
Veau, Celine
Gomez Mantilla, Jose David
Nock, Valerie
Fleury, Angele
PHARMACEUTICS, 2020, 12 (12) : 1 - 15
[46] P-hydroxylation of phenobarbital: Relationship to (s)-mephenytoin hydroxylation (CYP2C19) polymorphism
Hadama, A
Ieiri, I
Morita, T
Kimura, M
Urae, A
Irie, S
Kaneda, T
Mamiya, K
Tashiro, N
Higuchi, S
Otsubo, K
THERAPEUTIC DRUG MONITORING, 2001, 23 (02) : 115 - 118
[47] Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese
Takakubo, F
Kuwano, A
Kondo, I
PHARMACOGENETICS, 1996, 6 (03): : 265 - 267
[48] Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker
Noehr-Jensen, L.
Zwisler, S. T.
Larsen, F.
Sindrup, S. H.
Damkier, P.
Nielsen, F.
Brosen, K.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (09) : 887 - 894
[49] IMPACT OF CYP2C19 GENOTYPES AND EFAVIRENZ ON STEREOSELECTIVE METABOLISM OF OMEPRAZOLE IN HEALTHY VOLUNTEERS
Michaud, V.
Ogburn, E. T.
Kreutz, Y.
Thong, N.
Aregbe, A. O.
Quigg, T. C.
Epstein, N.
Callaghan, J. T.
Flockhart, D. A.
Desta, Z.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S17 - S17
[50] PHENOTYPING AND GENOTYPING OF S-MEPHENYTOIN HYDROXYLASE (CYTOCHROME-P450 2C19) IN A SHONA POPULATION OF ZIMBABWE
MASIMIREMBWA, C
BERTILSSON, L
JOHANSSON, I
HASLER, JA
INGELMANSUNDBERG, M
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) : 656 - 661

← 1 2 3 4 5 →